No (n=79) | % | |
Age (median, SD) | 60.2±8.6 years | |
Sex | ||
Male | 65 | (82) |
Female | 14 | (18) |
ECOG performance status | ||
0 | 62 | (78) |
1 | 17 | (22) |
Primary tumor site | ||
Oral cavity | 10 | (13) |
Oropharynx | 43 | (54) |
Hypopharynx | 14 | (18) |
Larynx | 12 | (15) |
T category | ||
T1 | 5 | (6) |
T2 | 12 | (15) |
T3 | 17 | (22) |
T4 | 45 | (57) |
N category | ||
N0 | 20 | (25) |
N1 | 18 | (23) |
N2 | 29 | (37) |
N3 | 12 | (15) |
UICC stage (according to TNM eighth edition) | ||
II* | 5 | (6) |
III | 30 | (38) |
IV | 44 | (56) |
Tobacco smoking status | ||
Current smoker | 33 | (42) |
Former smoker | 33 | (42) |
Never smoker | 13 | (16) |
Pack years of current/former smokers (median, SD) | 40.0±18.3 pack years | |
Intratumoral CD8 +immune cells (IC) (median, range) | 391 cells/mm² (12–5984) | |
PD-L1 status | ||
Tumor cells | ||
<25% | 61 | (77) |
≥25% | 18 | (23) |
IC area | ||
<25% | 49 | (62) |
≥25% | 30 | (38) |
Algorithm positivity | ||
Negative | 40 | (51) |
Positive | 39 | (49) |
HPV status all tumors (p16 positivity) | ||
Negative | 53 | (67) |
Positive | 26 | (33) |
HPV status Oropharynx only (p16 positivity) (n=43) | ||
Negative | 20 | (47) |
Positive | 23 | (53) |
*The TNM version changed from the seventh edition to the eighth edition during the trial. TNM classification in this table is according to the eighth edition. TNM classification according to the seventh edition is given in online supplemental table 1.
HPV, human papilloma virus; PD-L1, programmed death protein ligand 1; TNM, TNM Classification of Malignant Tumors.